SCHEMBL5560704

SCHEMBL5560704

COc1cc2c(Oc3cc(-c4ccncc4)[nH]n3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.55
▸ SRC P12931 10/20 0.52
▸ AURKA O14965 2/20 0.51
▸ KDR P35968 7/20 0.50
▸ EGFR P00533 6/20 0.50
▸ FLT4 P35916 3/20 0.49
▸ GAK O14976 2/20 0.49
▸ EPHB6 O15197 2/20 0.49
▸ RIPK2 O43353 2/20 0.49
▸ STK10 O94804 2/20 0.49
▸ MAP4K4 O95819 2/20 0.49
▸ CHEK2 O96017 2/20 0.49
▸ ABL1 P00519 2/20 0.49
▸ ERBB2 P04626 2/20 0.49
▸ LCK P06239 2/20 0.49
▸ LYN P07948 2/20 0.49
▸ RET P07949 2/20 0.49
▸ MET P08581 2/20 0.49
▸ HCK P08631 2/20 0.49
▸ FGR P09769 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565918 0.93 SRC (0.57) KDM1ASRCAURKAKDREGFR
Hydrochloric Acid SCHEMBL5566627 0.92 SRC (0.56) KDM1ASRCAURKAKDREGFR
SCHEMBL5561123 0.91 EGFR (0.56) KDM1ASRCKDREGFRFLT4
SCHEMBL5565947 0.91 KDR (0.55) KDM1ASRCAURKAKDREGFR
SCHEMBL5561384 0.91 KDM1A (0.54) KDM1ASRCAURKAKDREGFR
SCHEMBL5562291 0.91 SRC (0.51) KDM1ASRCAURKAKDREGFR
Hydrochloric Acid SCHEMBL5566884 0.91 KDR (0.55) KDM1ASRCAURKAKDREGFR
SCHEMBL5566089 0.89 KDM1A (0.52) KDM1ASRCAURKAKDREGFR
Hydrochloric Acid SCHEMBL5566084 0.88 KDM1A (0.51) KDM1ASRCAURKAKDREGFR
SCHEMBL5561216 0.88 KDM1A (0.49) KDM1ASRCAURKAKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US claimed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP claimed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP claimed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO claimed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US disclosed
EP-1119567-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-04 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed
Send feedback